
Abstract: P371
Type: Poster Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 17:15 - 18:45
Location: Poster area (Hall 7)
Background
Aims
The objective of this study was to measure the economic burden associated with the management of relapse following aHSCT and to evaluate the impact of treatment choice on survival and health care costs.
Methods
A retrospective medical chart review was conducted at Maisonneuve-Rosemont Hospital (HMR) after research and ethic committee approval. Patients were selected using the Hematopoietic Stem Cell Transplant (HSCT) program database. Eligible patients were diagnosed with acute leukemia (AL) or MDS and relapsed following a HLA identical aHSCT between January 1st 2011 and December 31st 2014. Patients’ and disease characteristics and relapse-related health care resource utilization were collected from the date of post transplant relapse until death or last follow-up. Canadian unit costs for each intervention/treatment were obtained from literature and governmental publications.
Results
Conclusion
Session topic: 35. Quality of life, palliative care, ethics and health economics
Keyword(s): Relapse, Cost analysis, Cellular therapy
Abstract: P371
Type: Poster Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 17:15 - 18:45
Location: Poster area (Hall 7)
Background
Aims
The objective of this study was to measure the economic burden associated with the management of relapse following aHSCT and to evaluate the impact of treatment choice on survival and health care costs.
Methods
A retrospective medical chart review was conducted at Maisonneuve-Rosemont Hospital (HMR) after research and ethic committee approval. Patients were selected using the Hematopoietic Stem Cell Transplant (HSCT) program database. Eligible patients were diagnosed with acute leukemia (AL) or MDS and relapsed following a HLA identical aHSCT between January 1st 2011 and December 31st 2014. Patients’ and disease characteristics and relapse-related health care resource utilization were collected from the date of post transplant relapse until death or last follow-up. Canadian unit costs for each intervention/treatment were obtained from literature and governmental publications.
Results
Conclusion
Session topic: 35. Quality of life, palliative care, ethics and health economics
Keyword(s): Relapse, Cost analysis, Cellular therapy